Rick Bienkowski
Stock Analyst at Cantor Fitzgerald
(0.36)
# 4,082
Out of 4,859 analysts
38
Total ratings
18.75%
Success rate
-29.62%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Rick Bienkowski
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LEGN Legend Biotech | Reiterates: Overweight | $55 | $36.59 | +50.31% | 3 | May 14, 2025 | |
| VERV Verve Therapeutics | Upgrades: Overweight | n/a | $6.39 | - | 4 | Apr 15, 2025 | |
| BEAM Beam Therapeutics | Reiterates: Overweight | n/a | $17.89 | - | 12 | Mar 12, 2025 | |
| ACLX Arcellx | Initiates: Overweight | n/a | $66.17 | - | 1 | Sep 3, 2024 | |
| NTLA Intellia Therapeutics | Reiterates: Overweight | $65 | $8.37 | +676.58% | 7 | Jun 24, 2024 | |
| CRBU Caribou Biosciences | Initiates: Neutral | n/a | $1.18 | - | 1 | Nov 8, 2023 | |
| EDIT Editas Medicine | Reiterates: Overweight | $14 | $2.03 | +589.66% | 6 | Sep 13, 2023 | |
| CRSP CRISPR Therapeutics AG | Maintains: Outperform | $112 → $107 | $41.52 | +157.71% | 4 | Aug 8, 2022 |
Legend Biotech
May 14, 2025
Reiterates: Overweight
Price Target: $55
Current: $36.59
Upside: +50.31%
Verve Therapeutics
Apr 15, 2025
Upgrades: Overweight
Price Target: n/a
Current: $6.39
Upside: -
Beam Therapeutics
Mar 12, 2025
Reiterates: Overweight
Price Target: n/a
Current: $17.89
Upside: -
Arcellx
Sep 3, 2024
Initiates: Overweight
Price Target: n/a
Current: $66.17
Upside: -
Intellia Therapeutics
Jun 24, 2024
Reiterates: Overweight
Price Target: $65
Current: $8.37
Upside: +676.58%
Caribou Biosciences
Nov 8, 2023
Initiates: Neutral
Price Target: n/a
Current: $1.18
Upside: -
Editas Medicine
Sep 13, 2023
Reiterates: Overweight
Price Target: $14
Current: $2.03
Upside: +589.66%
CRISPR Therapeutics AG
Aug 8, 2022
Maintains: Outperform
Price Target: $112 → $107
Current: $41.52
Upside: +157.71%